Suicide gene transfer using thymidine kinase (TK) and ganciclovir (GCV) treatment or the cytosine deaminase (CD)/5-fluorocytosine (5-FC) system represents the most widely used approach for gene therapy of cancer. However, molecular pathways and resistance mechanisms remain controversial for GCV-mediated cytotoxicity, and are virtually unknown for the CD/5-FC system. Here, we elucidated some of the cellular pathways in glioma cell lines that were transduced to express the TK or CD gene. In wild-type p53-expressing U87 cells, exposure to GCV and 5-FC resulted in a weak p53 response, although apoptosis was efficiently induced. Cell death triggered by GCV and 5-FC was independent of death receptors, but accompanied by mitochondrial alterations. Whereas expression of Bax remained unaffected, in particular, GCV and also 5-FC caused a decline in the level of Bcl-2. Similar findings were obtained in 9L and T98G glioma cells that express mutant p53, and also underwent mitochondrial apoptosis in both the TK/GCV and CD/ 5-FC system. Upon treatment of 9L cells with 5-FC, Bcl-x L expression slowly declined, whereas exposure to GCV resulted in the rapid proapoptotic phosphorylation of Bcl-x L . These data suggest that TK/GCV-and CD/5-FC-induced apoptosis does neither require p53 nor death receptors, but converges at a mitochondrial pathway triggered by different mechanisms of modulation of Bcl-2 proteins.
Introduction
As gene therapy of cancer, in particular suicide gene therapy, has entered several clinic trials, the factors limiting its efficacy have attracted increasing attention. Thus, target specificity, low in vivo transfection efficacy or limited cytotoxic effects are currently subjects of intense research (Rainov and Kramm, 2001; Kramm et al., 2003) . The rationale behind suicide gene therapy is that after targeted transfer of these genes into tumor cells, only tumor and neighboring cells will be rendered sensitive to their cytotoxic action. As suicide gene therapy is essentially a tumor-targeted chemotherapy, the systemic toxicity commonly associated with, and a major limitation of, conventional chemotherapy is avoided.
Two suicide genes that are widely used and being evaluated in the clinic are the herpes simplex virus type 1 (HSV) thymidine kinase (TK) enzyme and the Escherichia coli cytosine deaminase (CD) enzyme systems, which confer sensitivity to the prodrugs ganciclovir (GCV) and 5-fluorocytosine (5-FC), respectively (Hamel et al., 1996; Klatzmann et al., 1996; Kramm et al., 1997; Ichikawa et al., 2000; Rainov, 2000; Wei et al., 2004) . TK phosphorylates the nontoxic prodrug GCV, which then becomes phosphorylated by endogenous kinases to GCV triphosphate, causing chain termination and single-strand breaks upon incorporation into DNA (Moolten, 1986) . Moreover, not only cells expressing the transgene but also neighboring nontransduced tumor cells can undergo cell death by so-called bystander killing (Freeman et al., 1993; Kaneko and Tsukamoto, 1995) . In the CD/5-FC suicide gene system, CD deaminates the nontoxic pyrimidine 5-fluorocytosine to the cytotoxic 5-fluorouracil (5-FU) (Mullen et al., 1992; Schilsky, 1998) . 5-FU is then processed either to the ribonucleotide 5-fluorouracil triphosphate or to 5-fluoro-2-deoxyuridine-5-monophosphate. Whereas the former is incorporated into RNA and interferes with RNA processing, the latter irreversibly inhibits thymidylate synthase and interferes with DNA synthesis.
While the cellular pharmacology of 5-FC and GCV has been extensively characterized, surprisingly, very little is known about the mechanisms of how suicide gene approaches actually kill cancer cells and how cells might acquire resistance. Some recent reports demonstrated that the TK/GCV system induces apoptosis (Hamel et al., 1996; McMasters et al., 1998; Beltinger et al., 1999 Beltinger et al., , 2000 Glaser et al., 2001; Tomicic et al., 2002) . Induction of apoptosis is essentially executed by the activation of proteases of the caspase family, which can be achieved via two major signaling pathways, namely the extrinsic and intrinsic death pathways, both of which depend on the stimulus-induced formation of large multiprotein complexes Los et al., 1999) . Upon formation of the deathinducing signaling complex in the extrinsic death receptor pathway or the apoptosome in the intrinsic mitochondrial pathway, initiator caspases are activated through oligomerization resulting in the downstream activation of effector caspases and cleavage of numerous death substrates (Stroh and Schulze-Osthoff, 1998; Fischer et al., 2003) . It was reported that TK/ GCV-induced apoptosis requires p53, which then triggered the translocation of CD95 to the cell surface resulting in death receptor-mediated activation of caspases (Beltinger et al., 1999) . However, there were also reports demonstrating that apoptosis induced by TK/GCV does neither require p53 nor death receptors, but is essentially regulated via a Bcl-2 controlled mitochondrial pathway (Glaser et al., 2001; Tomicic et al., 2002) . Thus, the mechanism of TK/GCV-induced apoptosis remains unclear, and it is entirely unknown how the CD/5-FC system causes cell death of tumor cells.
Glioblastoma is a highly lethal neoplasm and has become a candidate tumor for the development of suicide gene therapy (Oldfield et al., 1993; Kramm et al., 1995; Nanda et al., 2001; Rainov and Kramm, 2001) . As the knowledge of the molecular events of TK/GCV-and CD/5-FC-mediated cytotoxicity and the mechanisms regulating sensitivity or resistance of tumor cells may be critical to improve their efficacy, we investigated and compared their mechanisms of action in glioma cells harboring either wild-type or mutant p53. Here, we report that TK/GCV-as well as CD/5-FC-induced apoptosis is death receptor-independent and can proceed in the absence of functional p53, but involves the mitochondrial death pathway that is controlled at the level of Bcl-2 family proteins. We also show that, although both prodrugs principally engage the mitochondrial pathway, they use different mechanisms to interfere with the balance of pro-and antiapoptotic Bcl-2 proteins.
Results

TK and CD gene transfer sensitizes malignant glioma cells to prodrug-induced apoptosis
We first investigated the cytotoxic mechanism of bacterial CD/5-FC and TK/GCV in U87 glioma cells that harbor a wild-type p53 gene (Asai et al., 1994; Van Meir et al., 1994) . The parental cells were resistant to GCV or 5-FC in the absence of TK and CD, but became highly sensitive to the prodrugs after TK and CD gene transfer, respectively. U87-cd and U87-tk cell lines displayed IC 50 doses (concentration inducing death in 50% of the cells within 3 days) for the corresponding prodrugs that were 100 or 5000 times lower than in the wild-type cells (data not shown). In contrast, actinomycin D that was used as control caused toxicity to a similar extent in both the parental cells and their transduced derivatives. Cytotoxicity caused by GCV and 5-FC in the transduced cells was mainly due to apoptosis, as assessed by typical morphological alterations including rounding up of the cells, detachment and membrane blebbing. DNA staining showed in addition chromatin condensation and subsequent nuclear fragmentation, while none of these alterations was observed after treatment of the parental cells with the two prodrugs (data not shown).
Induction of apoptosis by prodrug treatment was confirmed by measuring the formation of hypodiploid DNA. After 72 h, GCV induced apoptosis in more than 70% of the transduced U87 cells, while no apoptotic response was observed in parental U87 cells (Figure 1 ). Apoptosis induced by 5-FC was somehow delayed compared to GCV treatment. In principle, similar results were obtained when apoptosis was determined by phosphatidylserine exposure that was measured by annexin-V staining. Upon GCV treatment for 48-72 h, approximately 30% of the cells revealed apoptotic phosphatidylserine exposure, whereas incubation with 5-FC was less effective but also clearly induced apoptosis (Figure 2 ).
GCV and 5-FC induce S phase delay and G1 arrest, respectively
Since GCV-and 5-FC-induced apoptosis in U87 cells is a late response starting not earlier than 24 h after prodrug treatment, it indicated that postexposure cell cycle events might be involved. To elucidate this process in more detail, we followed cell cycle progression upon drug treatment. Flow cytometry (Figure 3a ) revealed that cells exposed to GCV were blocked in cell cycle progression and accumulated in the S phase. At 24 h after GCV treatment, B69% of the cells were arrested in S phase, whereas in untreated control cells the percentage of cells in S phase was 36%. In contrast, 5-FC appeared to arrest cells preferentially in the G0/G1 phase. Overall, the data show that during both the exposure to GCV and 5-FC cells were blocked in cell cycle progression, which, however, occurred in different phases of the cell cycle.
An important regulator of cell cycle arrest is p53, which induces the expression of several target genes including the cyclin-dependent kinase inhibitor p21 (May and May, 1999; Vousden and Lu, 2002) . Expression of p53 is normally maintained at a low level through a negative-feedback loop in which the p53-induced Mdm2 product interacts with p53 and targets it for proteasomal degradation (Momand et al., 1992; Haupt et al., 1997; Kubbutat et al., 1997) . Upon exposure of U87 cells to GCV, a significant increase in p53 expression was observed, which, however, occurred not earlier than after 48 h and remained constant for 72 h (Figure 3b ). In contrast, after 5-FC treatment expression of p53 was rather transient, as it peaked after 24 h and then declined. These differences corresponded to the expression levels of Mdm2, which was maximally expressed after 48 h in 5-FC-treated cells, when p53 expression declined. Treatment with GCV, interestingly, led to the increased expression of two Mdm2-specific protein bands, the full-length form and a faster migrating 60 kDa band that presumably represented a proteolytic fragment (Figure 3b ). The 60 kDa fragment of Mdm2 has been previously described to have lost the ability to target p53 for degradation, while maintaining its inhibitory effect on p53-mediated transcriptional activation (Chen et al., 1997; Erhardt et al., 1997) . In accordance, whereas p21 levels remained rather constant or even slightly decreased after GCV treatment, exposure to 5-FC induced a transient elevation of p21 expression.
5-FC-and GCV-mediated apoptosis involves the activation of a mitochondrial and death receptor-independent caspase pathway Apoptosis is essentially executed by proteases of the caspase family that can be activated by either a mitochondrial or a death receptor-dependent pathway . To assess the involvement of caspases, we measured their proteolytic activity in a colorimetric substrate assay using DEVD-pNA, a major substrate of caspase-3. Activation of caspases became evident in U87 cells 24 h upon GCV treatment and then steadily increased, while no effect was detectable in parental U87 cells under these conditions (Figure 4a ). Similar findings, though to a weaker extent, were observed when U87 cells were treated with 5-FC (Figure 4b ). 
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Since GCV-induced apoptosis has been reported to involve the death receptor CD95 (Beltinger et al., 1999; Wei et al., 1999) , we also investigated CD95 surface expression during treatment of cells with GCV and 5-FC. As measured by flow cytometry, none of the prodrugs increased surface expression of CD95 ( Figure 5a ). Neither was the expression of TNF-R1 altered during drug treatment when compared to stainings with isotype-matched antibodies ( Figure 5b ).
To measure mitochondrial alterations during GCV and 5-FC cytotoxicity, we determined the mitochondrial membrane potential DC m by staining of cells with the potential-sensitive dye 3,3 0 -dihexyloxacarbocyanine. Treatment with GCV and 5-FC resulted in a strong loss of DC m (Figure 6a and b). In particular, during exposure to GCV, loss of DC m preceded damage of the cell membrane, as assessed by double-staining with propidium iodide. Since mitochondrial alterations during apoptosis are regulated by the balance between proand antiapoptotic members of the Bcl-2 family (Daniel et al., 2003) , we next determined the expression levels of Bcl-2, Bcl-x L and Bax upon prodrug exposure using immunoblot analysis. Presumably, due to a selection advantage or other unknown reasons, from several cell clones tested U87-cd cells had consistently low basal expression levels of Bax (Figure 6c ), which corresponded to their increased Mdm-2 levels (see Figure 3b ). During incubation of U87-tk and U87-cd cells with either GCV or 5-FC, the levels of Bcl-x L as well as of Bax remained fairly constant (Figure 6c ). Treatment of cells with the transcriptional inhibitor actinomycin D, however, induced a strong decrease in Bcl-x L expression. Interestingly and in contrast to Bcl-x L and Bax, prodrug treatment resulted in the rapid decline of Bcl-2 expression. During GCV exposure a strong decrease of Bcl-2 expression became detectable even within 24 h. A slight but clearly visible downregulation of Bcl-2 was also induced when U87-cd cells were treated with 5-FC. Altogether, these data suggest that apoptosis induced by both prodrugs involved changes in the balance of Bcl-2 proteins that triggered a mitochondrial but death receptor-independent pathway.
GCV-and 5-FC-induced apoptosis can proceed in the absence of functional p53
Since the role of p53 for TK/GCV-induced apoptosis is controversial and has not been investigated in the CD/ 5-FC system, we next analysed the requirement of p53. For this purpose, we used suicide gene-transfected cells of the human glioma cell line T98G as well as of the rat glioma cell line 9L. In contrast to U87 cells that express functional p53, T98G cells bear a nonfunctional p53 missense mutation in codon 237 of exon 7 (Van Meir et al., 1994) . In 9L cells p53 is nonfunctional due a missense mutation in its essential DNA-binding region (Asai et al., 1994) . In the T98G cell line, several independent cell clones transduced with either the CD or the TK gene underwent apoptosis, whereas no cytotoxicity was observed in the parental cells (Figure 7a ). Similar to U87 cells, apoptosis induction by 5-FC was weaker in comparison to GCV. In 9L cells, GCV and 5-FC induced a roughly similar extent of apoptosis ( Figure 7b ). Nevertheless, caspase activation in 9L cells was less pronounced following exposure to 5-FC, while GCV treatment resulted in a strong increase in caspase activity (Figure 8b ). These events were accompanied by induction of mitochondrial Expression status of p53, Mdm2 and p21: U87-tk cells (left panels) and U87-cd cells (right panels) were either left untreated or exposed to GCV or 5-FC. U87-tk cells were additionally treated for 24 h with actinomycin D (ActD). After the indicated times, cell lysates were prepared and subjected to immunoblot analysis using specific antibodies against p53, Mdm2 and p21. Presumably due to a selection advantage, U87-cd cell clones consistently displayed higher basal expression levels of Mdm2. Note that in GCV-treated U87-tk cells Mdm2 is detected as a full-length protein and a truncated form of 60 kDa
Apoptotic mechanisms in TK/GCV and CD/5-FC suicide gene therapy U Fischer et al permeability transition, as measured by the loss of DC m (Figure 8a ). Double-staining with propidium iodide revealed that during GCV exposure most cells with reduced DC m still maintained their cell membrane integrity. During 5-FC treatment, in contrast, cells with reduced mitochondrial membrane potential also revealed cell membrane damage (data not shown).
Together with the less pronounced caspase activation, this finding might suggest that, in addition to apoptosis, 5-FC treatment might also trigger necrotic alterations in 9L cells. Similar to U87 cells, incubation of 9L cells with either 5-FC or GCV did not alter surface expression of CD95 (Figure 8c ) or TNF-R1 (data not shown), when compared to stainings with isotype-matched control antibodies. In addition, no induction of CD95, CD95 ligand or TNF-R1 expression was detected in RT-PCR experiments at the mRNA level (data not shown), further suggesting that death receptor pathways are not involved in drug-induced cell death. We also investigated the effect of drug treatment on the expression of Bcl-2 proteins. In contrast to U87 cells, Bcl-2 expression did not decline, but remained constant following exposure of 9L cells to GCV and even slightly increased during 5-FC treatment (Figure 8d) . No significant changes were also observed when Bax expression was analysed. Following treatment with 5-FC Bcl-x L levels decreased, which was, however, observed as a rather late event after 72 h. Interestingly, GCV treatment resulted in the accumulation of an additional Bcl-x L -specific protein band with reduced electrophoretic mobility. This protein band has been previously identified as a phosphorylated form of Bcl-x L with reduced antiapoptotic activity (Poruchynsky et al., 1998; Fan et al., 2000) . In summary, these results indicate that both 5-FC and GCV can induce apoptosis independently of p53 and trigger a mitochondrial death pathway. Our results also suggest that, even though both drugs converge at the mitochondrial pathway, their mechanism of interference with the balance of pro-and antiapoptotic Bcl-2 proteins might differ depending on the drug and cell system.
Discussion
The aim of the present study was to investigate molecular pathways leading to cell death by suicide gene therapy in brain tumor cells. Despite a plethora of laboratory studies confirming the efficacy of suicide gene therapy in glioma and other tumor models, the molecular events underlying TK/GCV cytotoxicity are unclear, and no studies have yet investigated the pathways involved in CD/5-FC-induced cell death of tumor cells.
We report that both the TK/GCV and the CD/5-FC suicide gene systems are potent inducers of apoptosis and trigger a mitochondrial, Bcl-2-controlled death pathway that is independent of death receptors. In addition, by employing cell lines expressing either wild type or mutant p53, we clearly demonstrate that GCV as well as 5-FC treatment can induce apoptosis in the absence of functional p53. Previously, p53 has been proposed to mediate CD95 aggregation and caspase activation in TK/GCV-treated neuroblastoma cells (Beltinger et al., 1999) . Other studies, in contrast, could not confirm a requirement of the p53 pathway in response to TK/GCV (Glaser et al., 2001; Tomicic et al., 2002) . It is important to note that even in p53-expressing U87 cells the exposure to GCV and 5-FC only triggered a rather moderate p53 response. Thus, in comparison to actinomycin D, after GCV treatment accumulation of p53 was rather weak and occurred as a late event. In addition, in CD/5-FC treated cells an only moderate and transient accumulation of p53 was noticed. This weak induction of p53 became also obvious by our observation that, in contrast to actinomycin D, after prodrug treatment p53 expression was only detectable by immunoblot analysis, but not by less sensitive immunocytochemical methods (data not shown).
The moderate induction of p53 during suicide gene therapy is presumably further counterbalanced by the induction of Mdm2, which not only inhibits the transactivating function of p53, but targets it also for Figure 4 Caspase activation during TK/GCV-and CD/5-FCmediated cytotoxicity. U87-tk cells (a) and U87-cd cells (b) were treated as described in Figure 1 . After the indicated times, cell lysates were prepared and assayed for caspase-3-like activity in a colorimetric assay using Ac-DEVD-pNA. Relative caspase activities were determined at 405 nM and are given as means7s.d. of three independent experiments Apoptotic mechanisms in TK/GCV and CD/5-FC suicide gene therapy U Fischer et al degradation (Momand et al., 1992; Haupt et al., 1997) . Whereas upon actinomycin D treatment, Mdm2 expression was significantly reduced in U87 cells, Mdm2 expression increased upon prodrug treatment. GCV treatment of U87 cells, in addition, resulted in the appearance of a truncated 60 kDa Mdm2 form that has been previously identified as a caspase-generated proteolytic fragment (Chen et al., 1997; Erhardt et al., 1997) . This Mdm2 cleavage product probably retains the ability to bind to p53 and inhibits its transcriptional Figure 5 TK/GCV-and CD/5-FC-induced apoptosis in U87 cells is not mediated by induction of CD95 or TNF-R1 surface expression. Cells were either left untreated or incubated with the respective prodrugs as described in Figure 1 . The percentage of cells expressing surface CD95 (a) or TNF-R1 (b) was monitored after 48 h by FACS analysis (grey area). The specificity of the stainings was controlled with isotype-matched control antibodies (white area). Furthermore, no inhibition of apoptosis was observed with antibodies neutralizing CD95 ligand or TNF (data not shown)
Apoptotic mechanisms in TK/GCV and CD/5-FC suicide gene therapy U Fischer et al activity, whereas the functional domain necessary for p53 degradation is deleted (Chen et al., 1997) . The weak induction of p53 and its inactivation by Mdm2 could certainly explain why no significant induction of the target genes p21 or Bax was found upon GCV treatment in U87 cells. The weak p53 response might also provide an explanation for the finding that exposure to GCV did not result in a G1 arrest, but an S phase delay. A p53-independent induction of S phase delay or G2/M arrest upon GCV exposure has been previously also found in other cell systems (Hamel et al., 1996; Wei et al., 1998; Tomicic et al., 2002) , and thus seems to be a general feature of GCV-treated cells. It is interesting to note that after treatment of 9L cells with GCV p21 was slightly induced under this condition, but presumably inactivated due to caspase-mediated cleavage into a 15 kDa fragment (data not shown). During treatment with the CD/5-FCsystem, U87 cells also displayed a weak G0/G1 arrest concomitant with a weak induction of p21. This observation was only a transient phenomenon, since p53 function was apparently impaired by elevated Mdm2 levels in the course of 5-FC incubation. Overall, our results indicate that p53-mediated apoptosis may account for only a small fraction of the cell death that occurs after insult with the CD/5-FC and TK/GCV prodrug systems. This notion is consistent with the fact that CD/5-FC and TK/GCV suicide gene therapies have demonstrated effectiveness against a variety of tumors that lack functional p53 (Wallace et al., 1996; Xie et al., 1999) . Nevertheless, it is worth mentioning that p53 might also affect apoptosis by transcriptionally independent mechanisms (Fridman and Lowe, 2003) .
A recent study proposed that p53 mediates the elevated surface expression of CD95 in TK/GCVtreated neuroblastoma cells, resulting in CD95-dependent apoptosis (Beltinger et al., 1999) . We find, however, that neither TK/GCV nor CD/5-FC therapy increased the surface expression of CD95 or of TNF-R1. A lack of inducible death receptor expression was not only found at the cell surface, but also at the mRNA level. Furthermore, neutralizing antibodies against CD95 ligand and TNF were unable to inhibit cytotoxicity of both prodrug systems (data not shown). No requirement of CD95 has recently been also proposed for GCVinduced apoptosis in another glioma cell line and CHO cells (Glaser et al., 2001; Tomicic et al., 2002) . Our results therefore suggest that the TNF and CD95 death receptor pathway is not only dispensable for TK/GCV, but also for CD/5-FC suicide gene therapy. Several previous studies by our and other groups suggest that, in contrast to death receptors, the mitochondrial pathway is more important for apoptosis induced upon DNA damage Wesselborg et al., 1999; Burek et al., 2001; Wieder et al., 2001) . This seems to be also true for the TK/GCV and CD/5-FC systems, which both induced prominent mitochondrial permeability transition. To investigate the contribution of the mitochondrial pathway in more detail, we determined the expression pattern of several Bcl-2 proteins. Prodrug treatment never led to a significant increase of the proapoptotic Bcl-2 protein Bax, an important mediator of cytochrome c release. As Bax is transcriptionally controlled by p53 (Miyashita and Reed, 1995) , this finding might lend further support to the view of a minor importance of p53 and, moreover, might indicate a particular role of Bak, a Bax-related Bcl-2 protein, in this scenario. While Bax levels remained unaltered, we interestingly observed that the expression of antiapoptotic Bcl-2 proteins was significantly changed following treatment of both p53-expressing and deficient cells with GCV and 5-FC. In GCVtreated U87 cells, the reduced mitochondrial membrane potential correlated with a downregulation of Bcl-2 expression, which thus might be responsible for induction of apoptotic cell death during suicide gene therapy.
There are several mechanisms that might be responsible for the decline in Bcl-2 expression. Although it has been reported that Bcl-2 expression is transcriptionally repressed by p53 (Miyashita et al., 1994; Wu et al., 2001) , we consider this possibility as unlikely in view of the minor role of p53 in both prodrug systems. Furthermore, during GCV treatment, the Bcl-2 decline actually preceded p53 accumulation. Recent evidence rather indicates that not impaired gene transcription, but the proteolytic degradation of Bcl-2, which could be either mediated by the proteasome or caspase activity might be responsible for its downregulation (Cheng et al., 1997; Dimmeler et al., 1999; Milosevic et al., 2003) . Interestingly, it has been recently reported that caspase-9 mediates the decline of Bcl-2 in GCV-treated hamster cells (Tomicic et al., 2002) . While downregulation of Bcl-2 might be the prime mechanism of apoptosis induction in the GCV-and 5-FC-treated U87 cells, in 9L cells Bcl-2 levels did not decline but even increased upon 5-FC treatment. In contrast to Bcl-2, we found that GCV treatment instead resulted in a strong phosphorylation of Bcl-x L . So far, phosphorylation of Bcl-x L has been described after treatment of cells with taxol and other microtubuli destabilizing agents that, similar to Apoptotic mechanisms in TK/GCV and CD/5-FC suicide gene therapy U Fischer et al GCV, also induce a late S and G2/M phase arrest (Poruchynsky et al., 1998; Fan et al., 2000) . There is evidence that phosphorylation of Bcl-x L and Bcl-2 is linked to its inactivation and decreased antiapoptotic activity, presumably by releasing Bax or other proapoptotic Bcl-2 proteins from a heteromeric complex (Kharbanda et al., 2000; Bassik et al., 2004) . Remarkably, unlike in the case of GCV treatment, no phosphorylation of Bcl-x L was detectable in 5-FCtreated 9L cells. Whether this difference is linked to the distinct cell cycle arrest mediated by the two prodrugs and the activation of a cell cycle-specific kinase remains to be investigated. Nevertheless, our finding suggests that not only the relative expression levels of pro-and antiapoptotic Bcl-2 proteins might be important for the efficacy of suicide gene therapy but also their post-translational modification by phosphorylation and degradation. Altogether, our findings demonstrate that TK/GCV-and CD/5-FC-induced apoptosis does not require p53 nor death receptors, but converges at a mitochondrial pathway that might be triggered by different mechanisms of post-translational processing of Bcl-2 proteins. These differences in the signaling by TK/GCV and CD/5-FC might also explain the synergistic therapeutic effect between prodrug systems that has been recently described in glioma cells (Aghi et al., 1998) .
Materials and methods
Plasmids and cell lines
The rat 9L gliosarcoma cell line and stably transduced derivates expressing either HSV-tk (9L-tk) or E. coli cd (9L-cd) have been previously described (Weizsaecker et al., 1981; Zimmer et al., 1997) and were generously provided by XO Breakefield (MGH, Charlestown, USA). For generation of an HSV-tk expressing U87 glioma cell line, the HSV-tk gene was inserted into the unique EcoRI restriction-site of the plasmid pBABE-hygro. The resulting vector pBABE-hygro/tk and the pCD2-vector expressing the E. coli cd gene (Mullen et al., 1992;  provided by M Blaese, NIH, Bethesda, USA) were transfected into U87 cells using Fugene reagent (Roche Diagnostics, Mannheim, Germany). Stable cell clones expressing the TK or CD suicide gene (U87-tk or U87-cd) under the control of the 5 0 -LTR-promoter of the Moloney murine leukemia virus were selected in hygromycin (0.1 mg/ml, Sigma-Aldrich, Deisenhofen, Germany) or neomycin (1 mg/ml, Gibco-BRL, Eggenstein, Germany). Human T98G glioma cells were transfected using lipofectamine and selected for suicide gene expression with neomycin. All cell lines were 9L cells transduced to express either TK or CD were treated with GCV and 5-FC, respectively. Loss of DC m was determined as described in Figure 6 . (b) Induction of caspase activation: caspase activity was measured as described in Figure 4 using the substrate Ac-DEVD-pNA. Note that caspase activation is considerably weaker after 5-FC than after GCV treatment, which corresponds to the observation that many cells with reduced DC m also showed cell membrane damage (data not shown). (c) Measurement of CD95 surface expression. Cells were treated for 48 h with GCV or 5-FC, before CD95 and TNF-R1 were determined by flow cytometry (grey area). Stainings with isotype-matched control antibodies revealed no differences compared to the specific antibodies, indicating that no increased CD95 or TNF-R1 surface expression was induced by prodrug treatment. Similar results were obtained when CD95 and TNF-R1 expression was assessed at the mRNA level by RT-PCR. maintained at 371C in a 5% CO 2 -enriched incubator and grown in RPMI-1640 culture medium (Biochrom KG, Berlin, Germany) supplemented with 10% heat-inactivated fetal bovine serum, 100 mg/ml penicillin/streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate.
Prodrug sensitivity assays
Cells were seeded in triplicate in six-well plates at a density of 1 Â 10 5 cells/well and were either left untreated or incubated with increasing concentrations of GCV (0.1 ng/ml to 100 mg/ml; Cymeven, Syntex GmbH, Aachen, Germany), 5-FC (0.1-3000 mg/ml; Sigma-Aldrich), or actinomycin D (0.1 ng/ml to 1 mg/ml; Sigma-Aldrich). Cells were counted with a Z1 cell counter (Coulter, Krefeld, Germany) after 96 h, and corresponding IC 50 doses were determined for each cell clone.
Detection of phosphatidylserine redistribution
Apoptotic cell death was determined by measuring binding of annexin-V-FITC upon exposure of phosphatidylserine to the outer cell surface (Essmann et al., 2003) . Cells were plated at a density of 4 Â 10 5 cells and treated with the different prodrugs. After the indicated times cells were collected, washed twice with PBS and resuspended in 200 ml binding buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) containing 2 ml annexin V-FITC (PharMingen). Cells were counterstained with the nonvital DNA dye propidium iodide (5 mg/ml) to distinguish early apoptotic cells with an intact cell membrane from late apoptotic or necrotic cells. Flow cytometric analysis was carried out on a FACSCalibur (Becton Dickinson; Heidelberg, Germany) equipped with CellQuest software. Results are given in % cells with increased fluorescence reflecting the number of annexin V-FITC stained, PI-negative cells.
Cell cycle analysis and measurement of hypodiploid DNA
The proportion of nuclei containing hypodiploid DNA was determined as previously described Totzke et al., 2003) . After drug treatment, cells were harvested and collected by centrifugation and fixed with 70% ice-cold ethanol for 30 min. After fixation cells were pelleted and incubated in PBS containing DNase-free RNaseA (Roche Diagnostics). Following incubation for 30 min at 371C, cells were pelleted again and finally resuspended in PBS containing 5 mg/ml propidium iodide. Nuclear DNA fragmentation and cell cycle distribution were then quantified using a FACSCalibur and evaluated with CellQuest and ModFit software. The number of apoptotic cells was calculated in % hypodiploidy (subG1).
Analysis of changes in mitochondrial membrane potential (DC m )
For measurement of mitochondrial permeability transition, 1 Â 10 6 cells/ml were incubated with 40 nM of the potentialsensitive dye 3,3 0 -dihexyloxacarbocyanine (DiOC 6 , Molecular Probes, Go¨ttingen, Germany) in PBS for 20 min at 371C. DiOC 6 accumulates in mitochondria with high DC m . Control experiments were performed by prior incubation of cells in 100 mM of the uncoupling agent carbamoyl cyanide mchlorophenylhydrazone (Sigma-Aldrich) for 30 min at 371C. Mitochondrial permeability transition was then quantified by flow cytometric determination of cells with decreased fluorescence. Plasma membrane integrity was monitored in parallel by staining with propidium iodide (5 mg/ml). Loss of DC m was additionally analysed by fluorescence microscopy using MitoTracker Green (Clontech, Heidelberg, Germany).
Cell extracts and immunoblotting
In total, 1 Â 10 6 cells were seeded in 24-or six-well plates and treated with corresponding prodrugs (GCV 10 mg/ml; 5-FC 100 mg/ml) or actinomycin D (1 mg/ml). After the indicated times, both the adherent and detached cells were harvested, washed in PBS and lysed in gel loading buffer (50 mM Tris/HCl pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol). Subsequently, proteins were separated under reducing conditions on a SDS-polyacrylamide gel and electroblotted onto Hybond membranes (Amersham Biosciences, Freiburg, Germany). Membranes were blocked for 1 h with 5% non-fat dry milk powder in TBS and then incubated overnight with primary antibodies diluted in 1% dry milk/ PBS. Membranes were washed four times with TBS/0.02% Triton X-100 and incubated with the peroxidase-conjugated goat anti-mouse IgG (diluted 1 : 1000; Santa Cruz) for 1 h at room temperature. Following extensive washing, the reaction was developed by enhanced chemiluminescent staining using Lumilight Plus (Roche Diagnostics, Mannheim, Germany). The mouse monoclonal antibodies anti-p53 (IgG 2b , clone PAB122), anti Bcl-x L (IgG 2a , clone 2H12), anti-Bax (IgG 1 , clone 6A7) and anti-Mdm2 (IgG 1 , clone SMP14) were obtained from PharMingen. Mouse anti-Bcl-2 (IgG 1 , clone C-2) and anti-p21 (IgG 2b , clone F-5) were purchased from Santa Cruz.
Detection of caspase activation
Caspase-3-like proteolytic activity was detected by a colorimetric assay (Clontech) following drug treatment for the indicated times. To this end, 10 ml of a cell extract was mixed with 90 ml of buffer containing 50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), 10% saccharose, 5 mM DTT and 2 ml colorimetric substrate (10 mM Ac-DEVD-pNA in DMSO). Samples were incubated at 371C, and the absorbance was measured in an ELISA reader at 405 nm.
Detection of death receptor and ligand expression
Surface expression of CD95 and TNF-R1 was detected by direct or indirect flow cytometric analysis. Cells were incubated with the conjugated or unconjugated primary antibodies for 1 h, followed by incubation with the conjugated antibodies for 30 min when appropriate. The specificity of staining was controlled by isotype control antibodies. The following antibodies were used: mouse IgG 1 -PE anti-human CD95 MoAb crossreactive with rat CD95 (Immunotech, Marseille, France) and the corresponding isotype control (mouse IgG 1 -PE, Immunotech), rat IgG 2a -FITC MoAb against rat and human CD95 ligand (Alexis, Giessen, Germany) and corresponding isotype-control (rat IgG 2a -FITC, Immunotech), anti-human/rat TNF-R1 mouse IgG 1 MoAb (R&D-Systems, Wiesbaden, Germany) and corresponding isotype control (mouse IgG 1 , BD Bioscience). As conjugated secondary antibody goat-anti-mouse IgG-PE (Serva) was used. Flow cytometric analyses were performed using a FACSCaliburt and CellQuestt software; dead cells were excluded by forward and sideward scatter gating and PI staining.
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